BioStock: SynAct Pharma’s acquisition of TXP Pharma concluded

Just before the end of 2022, SynAct Pharma announced its plans to acquire the Swiss biotech company TXP Pharma. The acquisition was approved on the Extraordinary General Meeting on January 12 and then completed on January 16. The addition of TXP’s platform puts SynAct Pharma in the forefront of resolution treatment through selective melanocortin stimulation and provides development opportunities in a broad range of autoimmune and inflammatory diseases.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/01/synact-pharmas-acquisition-of-txp-pharma-concluded/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se